Royal Bank of Canada
CSTL icon

Royal Bank of Canada’s Castle Biosciences CSTL Stock Holding History

Royal Bank of Canada’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Sell
177
-688
-80% -$22.5K ﹤0.01% 6480
2025
Q4 		$33K Sell
865
-32
-4% -$1.03K ﹤0.01% 5772
2025
Q3 		$20K Sell
897
-9,676
-92% -$197K ﹤0.01% 6207
2025
Q2 		$215K Buy
10,573
+1,486
+16% +$27.5K ﹤0.01% 5101
2025
Q1 		$182K Buy
9,087
+191
+2% +$4.73K ﹤0.01% 4766
2024
Q4 		$237K Sell
8,896
-2,355
-21% -$71.7K ﹤0.01% 4669
2024
Q3 		$321K Buy
11,251
+4,530
+67% +$115K ﹤0.01% 4446
2024
Q2 		$147K Buy
6,721
+3,569
+113% +$79.5K ﹤0.01% 4989
2024
Q1 		$70K Sell
3,152
-6,687
-68% -$145K ﹤0.01% 5373
2023
Q4 		$212K Buy
9,839
+5,380
+121% +$94.7K ﹤0.01% 5062
2023
Q3 		$76K Buy
4,459
+1,579
+55% +$27.6K ﹤0.01% 5550
2023
Q2 		$39K Buy
2,880
+830
+40% +$16.8K ﹤0.01% 5892
2023
Q1 		$47K Sell
2,050
-2,177
-52% -$53.2K ﹤0.01% 5651
2022
Q4 		$99K Buy
4,227
+1,120
+36% +$26K ﹤0.01% 5459
2022
Q3 		$81K Sell
3,107
-2,085
-40% -$58.5K ﹤0.01% 5452
2022
Q2 		$114K Buy
5,192
+3,530
+212% +$82K ﹤0.01% 5236
2022
Q1 		$75K Sell
1,662
-3,342
-67% -$138K ﹤0.01% 5830
2021
Q4 		$214K Buy
5,004
+1,977
+65% +$103K ﹤0.01% 5276
2021
Q3 		$202K Buy
3,027
+1,252
+71% +$88.1K ﹤0.01% 5163
2021
Q2 		$130K Buy
1,775
+235
+15% +$15.5K ﹤0.01% 5429
2021
Q1 		$106K Sell
1,540
-1,136
-42% -$85.4K ﹤0.01% 5417
2020
Q4 		$179K Sell
2,676
-1,799
-40% -$97.5K ﹤0.01% 4935
2020
Q3 		$230K Buy
4,475
+4,018
+879% +$179K ﹤0.01% 4447
2020
Q2 		$17K Buy
457
+264
+137% +$9.02K ﹤0.01% 5646
2020
Q1 		$6K Sell
193
-81
-30% -$2.44K ﹤0.01% 5970
2019
Q4 		$9K Buy
+274
New +$6.7K ﹤0.01% 6174

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's CSTL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Castle Biosciences (CSTL) stake by 80% in Q1 2026, selling an estimated $22.5K and leaving 177 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6480.

Royal Bank of Canada first reported a position in CSTL in Q4 2019 and has held it in 26 quarters since. The position peaked at $321K in Q3 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Royal Bank of Canada held 177 shares of Castle Biosciences worth $4K as of Q1 2026.
  • Royal Bank of Canada sold 688 Castle Biosciences shares in Q1 2026, an estimated $22.5K.
  • Castle Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6480 holding.
  • Royal Bank of Canada first reported a position in Castle Biosciences in Q4 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Castle Biosciences position peaked at $321K in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.